GPX4 and cancer: These observations are consistent with our analyses of the Cancer Dependency Map (DepMap) and Cancer Therapeutics Response Portal v2 (CTRPv2) datasets [20,21,22], which highlight that GPX4 gene dependency correlates with cancer cell line sensitivity to GPX4 inhibitors (including RSL3), Erastin, and APR-017 (analogue of Eprenetapopt) (Figure 2A,B).